Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
Siddharth SinghAntonio FacciorussoAbha G SinghNiels Vande CasteeleAmir ZarrinparLarry J ProkopEduardo L GrunvaldJeffrey R CurtisWilliam J SandbornPublished in: PloS one (2018)
Obesity is an under-reported predictor of inferior response to anti-TNF agents in patients with select immune-mediated inflammatory diseases. A thorough evaluation of obesity as an effect modifier in clinical trials is warranted, and intentional weight loss may serve as adjunctive treatment in patients with obesity failing anti-TNF therapy.
Keyphrases
- weight loss
- insulin resistance
- metabolic syndrome
- bariatric surgery
- high fat diet induced
- type diabetes
- weight gain
- rheumatoid arthritis
- clinical trial
- roux en y gastric bypass
- gastric bypass
- oxidative stress
- adipose tissue
- randomized controlled trial
- stem cells
- physical activity
- mesenchymal stem cells
- open label
- cell therapy